Genentech, Inc.
NEWS
Morningside Ventures launched a new biotech company called Adiso Therapeutics, and thriving startup Scenic Biotech scooped up €28 million ($31 million) in funding.
The clinical trial, called SKYLINE, is starting without results from other key ongoing studies on the drug.
CMS says it would only cover the cost of Biogen’s Aduhelm and any required scans “if they are enrolled in qualifying clinical trials.”
New two-year data from Phase III studies of Susvimo and Vabysmo reinforce the two drugs’ potential to improve the quality of life of patients diagnosed with DME and nAMD.
To address that lack of diversity, Medable and CVS have forged a collaboration to improve patient access to clinical trial research.
Biogen announced it was exercising its option to participate in Genentech’s development of mosunetuzumab under a long-standing collaboration for antibodies targeting CD20.
The FDA’s decision is based on positive results from several Phase III studies, including the TENAYA and LUCERNE clinical trials.
Clinical trial news definitely picked up this final week of January. Here’s a look.
Biogen and its partner Eisai Company released additional details about the Phase IV post-marketing study of the drug.
JOBS
IN THE PRESS